Home / Pharmaceutical company intelligence
Epharm Laboratories logo
Pharmaceutical company intelligence

Epharm Laboratories

Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.

Pharmaceutical manufacturer · Karachi · Pakistan

Karachi pharmaceutical manufacturer with more than two decades of operations, a broad registered portfolio and domestic and international market ambitions.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation25 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date30 Jul 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
A-40, Road No. 1, S.I.T.E. Super Highway Industrial Area, North Karachi, Karachi 75340, Pakistan · 75340
Phone
+92 300 0268033
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000598 E-Pharm Laboratories. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000598 144 linked products · source seen 25 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗ Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx144public portfolio records represented
REG126unique registrations represented
IDX144indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR139current validated price records
G67generic molecules in indexed catalogue
DF12dosage-form groups
TA14therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage97%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage95%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixEpharm LaboratoriesShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 25 Sep 2026Anti-infectives82 · 57%Cardiovascular17 · 12%Gastrointestinal & hepatology13 · 9%Vitamins, minerals & nutrition9 · 6%Hematology & thrombosis4 · 3%Respiratory & allergy4 · 3%CNS & mental health3 · 2%Other therapeutic areas12 · 8%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioEpharm LaboratoriesDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 25 Sep 2026144presentationsTablet59 · 41%Injection29 · 20%Capsule19 · 13%Syrup8 · 6%Drops7 · 5%Suspension7 · 5%Other forms15 · 10%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionEpharm LaboratoriesCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 25 Sep 2026137comparable productsBelow peer median76 · 55%Near peer median38 · 28%Above peer median23 · 17%Company median price position-6.5%Lowest-price equivalents21Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsEpharm LaboratoriesCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 25 Sep 2026Nabiqasim Industries (Pvt) Ltd.,42 shared63% overlapMediate Pharmaceutical Pvt Ltd39 shared58% overlapNeutro Pharma (Pvt.) Ltd.,38 shared57% overlapCCL Pharmaceuticals (Pvt.) Limited37 shared55% overlapZafa Pharmaceutical Laboratories (P…37 shared55% overlapBosch Pharmaceuticals (Pvt) Ltd.36 shared54% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives82 products · 57%
Cardiovascular17 products · 12%
Gastrointestinal & hepatology13 products · 9%
Vitamins, minerals & nutrition9 products · 6%
Hematology & thrombosis4 products · 3%
Respiratory & allergy4 products · 3%
CNS & mental health3 products · 2%
Dermatology2 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Fluoroquinolone antibacterials15 products · 10%
Third-generation cephalosporins14 products · 10%
Antimalarials11 products · 8%
Antifungals9 products · 6%
Vitamins / minerals / hematinics9 products · 6%
First-generation cephalosporins6 products · 4%
Aminoglycoside antibacterials5 products · 3%
Macrolide antibacterials5 products · 3%
Formulation footprint

Dosage forms

Tablet59 products
Injection29 products
Capsule19 products
Syrup8 products
Drops7 products
Suspension7 products
Cream4 products
Infusion4 products
Gel2 products
Ointment2 products
Solution2 products
Pessary1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 KeleyCephalexin 6presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #2 TeltanTelmisartan + Hydrochlorothiazide 5presentations 40 mg + 12.5 mg, 80 mg + 12.5 mg · Tablet #3 AstronMoxifloxacin 4presentations 400 mg, 400 mg/250 mL, 5 mg/mL · Tablet, Infusion, Drops #4 EpanCefixime 4presentations 100 mg/5 mL, 200 mg, 400 mg · Suspension, Capsule #5 FlociprinCiprofloxacin 4presentations 200 mg/100 mL, 250 mg, 500 mg, 750 mg · Infusion, Tablet #6 TaripharmOfloxacin 4presentations 0.3 %, 200 mg, 200 mg/100 mL, 400 mg · Drops, Tablet, Infusion
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median7655% of comparable products
Near market median38within ±5% of median
Above market median2317% of comparable products
Lowest-price equivalents21ties included
Company median price position -6.5% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Ephagent 40 mg/mLGentamicin · Injection · 2mlx25's PKR 11.85/mL-53.4% vs market median Keley 500 mgCephalexin · Capsule · 16's PKR 14.49/capsule-52.9% vs market median Ephagent 40 mg/mLGentamicin · Injection · 2mlx5's PKR 12.23/mL-52.0% vs market median Conate 1 %Clotrimazole · Cream · 15gm PKR 3.20/g-49.5% vs market median PC-Trax 250 mgCeftriaxone · Injection · 1 Vial PKR 104.84/vial/unit-45.5% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 42shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 39shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 38shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 37shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 37shared generics Bosch Pharmaceuticals (Pvt) Ltd.258 products · 74 generics 36shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers126Distinct registrations among indexed, published, presentation-validated products only
Verified price observations144
Products with a verified price144
Products with multiple price observations0
Source records with multiple versions144
Latest portfolio source check22 Sep 2026
Latest effective price date30 Jul 2026
Latest source observation25 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

126 unique registration(s) · 144 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Ephamic Tranexamic acid 500 mg Capsule 20’s 096273 PKR 413.47 PKR 20.67/capsule Near median
Ephamic Tranexamic acid 250 mg/5 mL Injection 5mlx10’s 098596 PKR 805.92 PKR 16.12/mL 44% above median
Ephamic Tranexamic acid 250 mg/5 mL Injection 5mlx5’s 098596 PKR 402.96 PKR 16.12/mL 44% above median
Ephamide Furosemide 20 mg/2 mL Injection 2mlx10's 044164 PKR 64.84 PKR 3.24/mL Near median
Ephamide Furosemide 20 mg/2 mL Injection 2mlx50's 044164 PKR 312.21 PKR 3.12/mL 8% below median
Ephasaline Nasal Sodium chloride 0.65 % Drops 30ml 118095 PKR 16.55 PKR 0.55/mL No comparator
Ephtum Ceftazidime 250 mg Injection 1 Vial 045467 PKR 155.32 PKR 155.32/vial/unit Near median
Ephtum Ceftazidime 500 mg Injection 1 Vial 045468 PKR 252.38 PKR 252.38/vial/unit Near median
Ephtum Ceftazidime 1 g Injection 1 Vial 045469 PKR 465.95 PKR 465.95/vial/unit Near median
Eptrim Artemether 20 mg/mL Injection 1mlx6's 076485 PKR 495.53 PKR 82.59/mL 21% below median
Eptrim Artemether 40 mg/mL Injection 1mlx10's 076486 PKR 693.74 PKR 69.37/mL 44% below median
Eptrim Artemether 80 mg/mL Injection 1mlx6's 076487 PKR 679.51 PKR 113.25/mL 40% below median
Eptrim-DS 40 Artemether + Lumefantrine 40 mg + 240 mg Tablet 8's 075827 PKR 523.28 PKR 65.41/tablet Near median
Eptrim-M 20 Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 075826 PKR 621.27 PKR 38.83/tablet Near median
Eptrim-X 80 Artemether + Lumefantrine 80 mg + 480 mg Tablet 6's 075828 PKR 654.10 PKR 109.02/tablet Near median
Eptrim-X 80 Artemether + Lumefantrine 80 mg + 480 mg Tablet 4's 075828 PKR 436.07 PKR 109.02/tablet Near median
Ethanzap-10 Olanzapine 10 mg Tablet 10's 104337 PKR 214.51 PKR 21.45/tablet 33% below median
Ethanzap-5 Olanzapine 5 mg Tablet 10's 104336 PKR 121.55 PKR 12.16/tablet 34% below median
Faremicin Fosfomycin 500 mg Capsule 12's 104329 PKR 171.60 PKR 14.30/capsule 23% below median
Feofar Letrozole 2.5 mg Tablet 30's 104332 PKR 9,004.07 PKR 300.14/tablet 27% below median
Feofar Letrozole 2.5 mg Tablet 10's 104332 PKR 3,001.36 PKR 300.14/tablet 27% below median
Fledore Fluoxetine 20 mg Capsule 10’s 090960 PKR 126.20 PKR 12.62/capsule Near median
Flociprin Ciprofloxacin 250 mg Tablet 1x10's 044169 PKR 232.98 PKR 23.30/tablet 8% below median
Flociprin Ciprofloxacin 500 mg Tablet 1x10's 044170 PKR 291.21 PKR 29.12/tablet 32% below median
Flociprin Ciprofloxacin 200 mg/100 mL IV infusion 100ml 061702 PKR 194.15 PKR 1.94/mL 16% below median
Flociprin Ciprofloxacin 750 mg Tablet 10's 128003 PKR 237.22 PKR 23.72/tablet 41% below median
Follinemic Elemental Iron 40 mg/15 mL Syrup 250ml 044349 PKR 721.49 PKR 2.89/mL 6% below median
Follinemic Elemental Iron 40 mg/15 mL Syrup 60ml 044349 PKR 188.30 PKR 3.14/mL 7% above median
Follinemic Elemental Iron 40 mg/15 mL Syrup 120ml 044349 PKR 356.78 PKR 2.97/mL Near median
Frutcee Chewable Ascorbic acid 500 mg Chewable tablet 4x10's 104320 PKR 49.57 PKR 1.24/tablet 7% below median
Iropharm Elemental Iron 100 mg Tablet 1x10's 047489 PKR 138.75 PKR 13.88/tablet Near median
Iropharm Elemental Iron 50 mg/5 mL Syrup 60ml 083956 PKR 138.75 PKR 2.31/mL Near median
Iropharm-F Iron + Folic acid 100 mg + 0.35 mg Tablet 2x10’s 089348 PKR 188.30 PKR 9.42/tablet 35% below median
Iropharm-F Iron + Folic acid 50 mg/5 mL + 0.35 mg/5 mL Syrup 120ml 112725 PKR 265.99 PKR 2.22/mL 6% below median
IT Itraconazole 100 mg Capsule 4’s 093012 PKR 506.46 PKR 126.62/capsule 13% below median
Izmepra Omeprazole 20 mg Capsule 100's 070821 PKR 1,836.62 PKR 18.37/capsule 7% below median
Izmepra Omeprazole 20 mg Capsule 14's 070821 PKR 279.58 PKR 19.97/capsule Near median
Izmepra Omeprazole 40 mg Capsule 2 x 7's 110063 PKR 353.17 PKR 25.23/capsule 27% below median
Keley Cephalexin 125 mg/5 mL Dry suspension 60ml 058414 PKR 114.55 PKR 1.91/mL 5% above median
Keley Cephalexin 250 mg/5 mL Dry suspension 60ml 058415 PKR 198.03 PKR 3.30/mL 15% above median
Keley Cephalexin 250 mg Capsule 12's 058416 PKR 198.03 PKR 16.50/capsule 8% above median
Keley Cephalexin 250 mg Capsule 16's 058416 PKR 176.68 PKR 11.04/capsule 30% below median
Keley Cephalexin 500 mg Capsule 12's 058417 PKR 396.42 PKR 33.04/capsule 7% above median
Keley Cephalexin 500 mg Capsule 16's 058417 PKR 231.91 PKR 14.49/capsule 53% below median
Klath Clarithromycin 250 mg Tablet 1x10's 061892 PKR 475.71 PKR 47.57/tablet Near median
Klath Clarithromycin 500 mg Tablet 1x10's 061899 PKR 863.96 PKR 86.40/tablet Near median
L-Tan Losartan 50 mg Tablet 2x10's 061894 PKR 388.29 PKR 19.41/tablet 6% below median
Lacnan Lactulose 3.35 g/5 mL Syrup 120ml 047183 PKR 287.33 PKR 2.39/mL Near median
Levopharm Levofloxacin 250 mg Tablet 1x10's 044347 PKR 388.29 PKR 38.83/tablet 20% below median
Levopharm Levofloxacin 500 mg Tablet 1x10's 044348 PKR 776.59 PKR 77.66/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Epharm Laboratories — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 25, 2026, from https://medinfobase.com/company/epharm-laboratories/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.